{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T13:17:31Z","timestamp":1792329451385,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008736","name":"Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["IT2010003"],"award-info":[{"award-number":["IT2010003"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["IT2010003"],"award-info":[{"award-number":["IT2010003"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["IT2010003"],"award-info":[{"award-number":["IT2010003"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["IT2010003"],"award-info":[{"award-number":["IT2010003"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Ministry of Education, Government of Chile | National Commission for Scientific and Technological Research | Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["IT2010003"],"award-info":[{"award-number":["IT2010003"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41397-026-00411-7","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:58:18Z","timestamp":1776711498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4186-5221","authenticated-orcid":false,"given":"Maximiliano","family":"Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie C.","family":"Cerpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Cay\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0645-6686","authenticated-orcid":false,"given":"Valentina","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-5320","authenticated-orcid":false,"given":"Luis A.","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"411_CR1","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). 2021. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-%28cvds%29"},{"key":"411_CR2","unstructured":"Ministerio de Salud, Departamento de Estad\u00edsticas e Informaci\u00f3n de Salud (DEIS). Tasa de mortalidad general en Chile. 2023. Available from: https:\/\/informesdeis.minsal.cl\/SASVisualAnalytics\/?reportUri=%2Freports%2Freports%2F4013de47-a3c2-47b8-8547-075525e4f819"},{"key":"411_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397\u2013404. https:\/\/doi.org\/10.1002\/cpt.668","journal-title":"Clin Pharmacol Ther"},{"key":"411_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","volume":"62","author":"M Pirmohamed","year":"2006","unstructured":"Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62:509\u201311. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02806.x","journal-title":"Br J Clin Pharmacol"},{"key":"411_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","volume":"116","author":"JL Anderson","year":"2007","unstructured":"Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.737312","journal-title":"Circulation"},{"key":"411_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fphar.2020.00325","volume":"11","author":"A Roco","year":"2020","unstructured":"Roco A, Nieto E, Su\u00e1rez M, Rojo M, Bertoglia MP, Ver\u00f3n G, et al. A pharmacogenetically guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study. Front Pharmacol. 2020;11:325. https:\/\/doi.org\/10.3389\/fphar.2020.00325. Corrigendum in: Front Pharmacol. 2025; 16: 1588440. 10.3389\/fphar.2025.1588440","journal-title":"Front Pharmacol"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1161\/circoutcomes.108.808592","volume":"2","author":"AR Patrick","year":"2009","unstructured":"Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009;2:429\u201336. https:\/\/doi.org\/10.1161\/circoutcomes.108.808592","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"411_CR8","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1038\/nmeth.f.258","volume":"6","author":"J McKinney","year":"2009","unstructured":"McKinney J, Lems R, Gundry C. CYP2C9 and VKORC1 genotyping reagents from Idaho Technology: rapid turn-around, accurate results. Nat Methods. 2009;6:v\u2013vi. https:\/\/doi.org\/10.1038\/nmeth.f.258","journal-title":"Nat Methods"},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40273-023-01309-z","volume":"42","author":"A Hafeez","year":"2024","unstructured":"Hafeez A, Cipriano LE, Kim RB, Zaric GS, Schwarz UI, Sarma S. Cost-effectiveness analysis of pharmacogenomics (PGx)-based warfarin, apixaban, and rivaroxaban versus standard warfarin for the management of atrial fibrillation in Ontario, Canada. Pharmacoeconomics. 2024;42:69\u201390. https:\/\/doi.org\/10.1007\/s40273-023-01309-z","journal-title":"Pharmacoeconomics"},{"key":"411_CR10","unstructured":"Fondo Nacional de Salud (FONASA). Genotipificaci\u00f3n. 2025. Available from: https:\/\/www.fonasa.cl\/sites\/fonasa\/adjuntos\/6_Nuevas_Prestaciones_Genetica_BiologiaMolecular_MAI_2019"},{"key":"411_CR11","unstructured":"Fondo Nacional de Salud (FONASA). Acenocumarol. 2025. Available from: https:\/\/nuevo.fonasa.gob.cl\/sites\/fonasa\/adjuntos\/Listado%20precios%20preferentes%20Convenio%20Farmacias%202023"},{"key":"411_CR12","unstructured":"Superintendencia de Salud (SuperSalud). Hemorragia subaracnoidea secundaria a ruptura de aneurismas cerebrales. 2025. Available from: https:\/\/www.superdesalud.gob.cl\/orientacion-en-salud\/hemorragia-subaracnoidea-secundaria-a-ruptura-de-aneurismas-cerebrales\/"},{"key":"411_CR13","unstructured":"Superintendencia de Salud (SuperSalud). Ataque cerebrovascular isqu\u00e9mico en personas de 15 a\u00f1os y m\u00e1s. 2025. Available from: https:\/\/www.superdesalud.gob.cl\/orientacion-en-salud\/ataque-cerebrovascular-isquemico-en-personas-de-15-anos-y-mas\/"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41436-019-0667-y","volume":"22","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Swanson KM, Rojas RL, Wang Z, St Sauver JL, Visscher SL, et al. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med. 2020;22:475\u201386. https:\/\/doi.org\/10.1038\/s41436-019-0667-y","journal-title":"Genet Med"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archinte.167.3.229","volume":"167","author":"SE Kimmel","year":"2007","unstructured":"Kimmel SE. The influence of patient adherence on anticoagulation control with warfarin. Arch Intern Med. 2007;167:229\u201335. https:\/\/doi.org\/10.1001\/archinte.167.3.229","journal-title":"Arch Intern Med"},{"key":"411_CR16","unstructured":"World Bank. GDP per capita (current US$) \u2013 Chile. 2023. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=CL"},{"key":"411_CR17","unstructured":"Carrasco M Propuesta de un algoritmo farmacogen\u00e9tico para optimizar la dosificaci\u00f3n inicial de acenocumarol e indicadores de calidad de la terapia anticoagulante en pacientes con fibrilaci\u00f3n auricular [master\u2019s thesis]. Santiago: Universidad de Chile; 2024."},{"key":"411_CR18","unstructured":"Ward ZJ Amua \u2013 an open-source modelling framework and probabilistic programming language. In: Computational Epidemiology: Methods and Applications for Global Health [dissertation]. Harvard University; 2021. Available from: https:\/\/github.com\/zward\/Amua"},{"key":"411_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12872-025-04703-x","volume":"25","author":"F Qi","year":"2025","unstructured":"Qi F, Wu J, Xia Z, Xie S, Chen X, Zheng H, et al. Clinical characteristics, adherence to anticoagulation therapy and prognosis in patients with atrial fibrillation: a real-life study. BMC Cardiovasc Disord. 2025;25:263 https:\/\/doi.org\/10.1186\/s12872-025-04703-x","journal-title":"BMC Cardiovasc Disord"},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","volume":"150","author":"MH Eckman","year":"2009","unstructured":"Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73\u201383.","journal-title":"Ann Intern Med"},{"key":"411_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000011.pub4","volume":"2014","author":"R Nieuwlaat","year":"2014","unstructured":"Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014:CD000011 https:\/\/doi.org\/10.1002\/14651858.CD000011.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"411_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106949","volume":"197","author":"V Fragoulakis","year":"2023","unstructured":"Fragoulakis V, Roncato R, Bignucolo A, Patrinos GP, Toffoli G, Cecchin E, et al. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. Pharmacol Res. 2023;197:106949 https:\/\/doi.org\/10.1016\/j.phrs.2023.106949","journal-title":"Pharmacol Res"},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ajhg.2023.08.015","volume":"110","author":"SG Medina-Mu\u00f1oz","year":"2023","unstructured":"Medina-Mu\u00f1oz SG, Ortega-Del Vecchyo D, Cruz-Hervert LP, Ferreyra-Reyes L, Garc\u00eda-Garc\u00eda L, Moreno-Estrada A, et al. Demographic modeling of admixed Latin American populations from whole genomes. Am J Hum Genet. 2023;110:1804\u201316. https:\/\/doi.org\/10.1016\/j.ajhg.2023.08.015","journal-title":"Am J Hum Genet"},{"key":"411_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1211712","volume":"14","author":"A L\u00f3pez-Cort\u00e9s","year":"2023","unstructured":"L\u00f3pez-Cort\u00e9s A, Esper\u00f3n P, Mart\u00ednez MF, Redal MA, Lazarowski A, Varela NM, et al. Editorial: pharmacogenetics and pharmacogenomics in Latin America: ethnic variability, new insights in advances and perspectives: a RELIVAF-CYTED initiative, volume II. Front Pharmacol. 2023;14:1211712 https:\/\/doi.org\/10.3389\/fphar.2023.1211712","journal-title":"Front Pharmacol"},{"key":"411_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cpt.1598","volume":"107","author":"F Rodrigues-Soares","year":"2020","unstructured":"Rodrigues-Soares F, Pe\u00f1as-Lled\u00f3 EM, Tarazona-Santos E, Sosa-Mac\u00edas M, Ter\u00e1n E, L\u00f3pez-L\u00f3pez M, et al. Genomic ancestry, CYP2D6, CYP2C9, and CYP2C19 among Latin Americans. Clin Pharmacol Ther. 2020;107:257\u201368. https:\/\/doi.org\/10.1002\/cpt.1598","journal-title":"Clin Pharmacol Ther"},{"key":"411_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110916","volume":"27","author":"K Karamperis","year":"2024","unstructured":"Karamperis K, Katz S, Melograna F, Ganau FP, Van Steen K, Patrinos GP, et al. Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity. iScience. 2024;27:110916 https:\/\/doi.org\/10.1016\/j.isci.2024.110916","journal-title":"iScience"},{"key":"411_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41397-022-00272-w","volume":"22","author":"A Sukri","year":"2022","unstructured":"Sukri A, Salleh MZ, Masimirembwa C, Teh LK. A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges. Pharmacogenomics J. 2022;22:147\u201359. https:\/\/doi.org\/10.1038\/s41397-022-00272-w","journal-title":"Pharmacogenomics J"},{"key":"411_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/PPL-140390","volume":"16","author":"ME Olivera","year":"2014","unstructured":"Olivera ME, Uema SAN, Roma\u00f1uk CB, Caffaratti M, Carvalho-Mastroianni P, Rossi F, et al. Regulatory issues on pharmacovigilance in Latin American countries. Pharm Policy Law. 2014;16:289\u2013312. https:\/\/doi.org\/10.3233\/PPL-140390","journal-title":"Pharm Policy Law"},{"key":"411_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1175737","volume":"14","author":"A Salas-Hern\u00e1ndez","year":"2023","unstructured":"Salas-Hern\u00e1ndez A, Galleguillos M, Carrasco M, L\u00f3pez-Cort\u00e9s A, Redal MA, Fonseca-Mendoza D, et al. An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug\/gene pairs in Latin America and the Caribbean. Front Pharmacol. 2023;14:1175737 https:\/\/doi.org\/10.3389\/fphar.2023.1175737","journal-title":"Front Pharmacol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00411-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:18Z","timestamp":1782195138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00411-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00411-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7411548\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was based on secondary data analysis and simulation modelling, using previously published and non-identifiable data. All methods were carried out in accordance with relevant guidelines and regulations. No direct involvement of human participants or animals was performed, and no identifiable personal data were used. Therefore, ethics committee approval and informed consent were not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"15"}}